Role of respiratory intermediate care units during the SARS-CoV-2 pandemic.


Journal

BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563

Informations de publication

Date de publication:
13 Jul 2021
Historique:
received: 15 03 2021
accepted: 09 06 2021
entrez: 14 7 2021
pubmed: 15 7 2021
medline: 17 8 2021
Statut: epublish

Résumé

The SARS-CoV2 pandemic increased exponentially the need for both Intensive (ICU) and Intermediate Care Units (RICU). The latter are of particular importance because they can play a dual role in critical and post-critical care of COVID-19 patients. Here, we describe the setup of 2 new RICUs in our institution to face the SARS-CoV-2 pandemic and discuss the clinical characteristics and outcomes of the patients attended. Retrospective analysis of the characteristics and outcomes of COVID-19 patients admitted to 2 new RICUs built specifically in our institution to face the first wave of the SARS-CoV-2 pandemic, from April 1 until May 30, 2020. During this period, 106 COVID-19 patients were admitted to these 2 RICUs, 65 of them (61%) transferred from an ICU (step-down) and 41 (39%) from the ward or emergency room (step-up). Most of them (72%) were male and mean age was 66 ± 12 years. 31% of them required support with oxygen therapy via high-flow nasal cannula (HFNC) and 14% non-invasive ventilation (NIV). 42 of the 65 patients stepping down (65%) had a previous tracheostomy performed and most of them (74%) were successfully decannulated during their stay in the RICU. Length of stay was 7 [4-11] days. 90-day mortality was 19% being significantly higher in stepping up patients than in those transferred from the ICU (25 vs. 10% respectively; p < 0.001). RICUs are a valuable hospital resource to respond to the challenges of the SARS-CoV-2 pandemic both to treat deteriorating and recovering COVID-19 patients.

Identifiants

pubmed: 34256747
doi: 10.1186/s12890-021-01593-5
pii: 10.1186/s12890-021-01593-5
pmc: PMC8275902
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

228

Informations de copyright

© 2021. The Author(s).

Références

PLoS One. 2020 Dec 16;15(12):e0243968
pubmed: 33326484
Med Intensiva (Engl Ed). 2020 Aug - Sep;44(6):363-370
pubmed: 32336551
Arch Bronconeumol (Engl Ed). 2019 Dec;55(12):634-641
pubmed: 31587917
Rev Esp Anestesiol Reanim (Engl Ed). 2020 May;67(5):261-270
pubmed: 32307151
JAMA Intern Med. 2020 Sep 1;180(9):1156-1163
pubmed: 32356867
PLoS One. 2020 Jul 10;15(7):e0235653
pubmed: 32649661
Eur Respir J. 2020 Nov 5;56(5):
pubmed: 32747398
Arch Bronconeumol. 2005 Sep;41(9):505-12
pubmed: 16194514
Lancet Respir Med. 2020 Jul;8(7):717-725
pubmed: 32422180
BMC Med. 2020 Sep 3;18(1):270
pubmed: 32878619
Eur Respir J. 2017 Aug 31;50(2):
pubmed: 28860265
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143

Auteurs

Mónica Matute-Villacís (M)

Servei de Pneumologia i Al·lèrgia Respiratòria, Institut Clínic Respiratori, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain.

Jorge Moisés (J)

Servei de Pneumologia i Al·lèrgia Respiratòria, Institut Clínic Respiratori, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain.
CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.

Cristina Embid (C)

Servei de Pneumologia i Al·lèrgia Respiratòria, Institut Clínic Respiratori, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain.
CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.

Judith Armas (J)

Servei de Pneumologia i Al·lèrgia Respiratòria, Institut Clínic Respiratori, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain.

Isabel Fernández (I)

Servei de Pneumologia i Al·lèrgia Respiratòria, Institut Clínic Respiratori, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain.

Montserrat Medina (M)

Servei de Pneumologia i Al·lèrgia Respiratòria, Institut Clínic Respiratori, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain.

Miquel Ferrer (M)

Servei de Pneumologia i Al·lèrgia Respiratòria, Institut Clínic Respiratori, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain.
CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.

Oriol Sibila (O)

Servei de Pneumologia i Al·lèrgia Respiratòria, Institut Clínic Respiratori, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain.
CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.

Joan Ramón Badia (JR)

Servei de Pneumologia i Al·lèrgia Respiratòria, Institut Clínic Respiratori, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain. jrbadia@clinic.cat.
CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain. jrbadia@clinic.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH